uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro.
Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Obstetrik & gynekologi. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för kvinnors och barns hälsa, Obstetrik & gynekologi. (Klinisk och experimentell reproduktionsbiologi/Olovsson)
Vise andre og tillknytning
2013 (engelsk)Inngår i: Menopause: The Journal of the North American Menopause, ISSN 1072-3714, E-ISSN 1530-0374, Vol. 20, nr 2, s. 162-168Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE:

The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.

METHODS:

A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.

RESULTS:

In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitor-treated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.

CONCLUSIONS:

Our findings suggest that sexual dysfunction in aromatase inhibitor-treated women is a greatly underestimated problem.

sted, utgiver, år, opplag, sider
2013. Vol. 20, nr 2, s. 162-168
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-185540DOI: 10.1097/gme.0b013e31826560daISI: 000314342600010PubMedID: 22990756OAI: oai:DiVA.org:uu-185540DiVA, id: diva2:572043
Tilgjengelig fra: 2012-11-26 Laget: 2012-11-26 Sist oppdatert: 2017-12-07bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Stavreus-Evers, AnneliKallak, Theodora KunovacSundström Poromaa, Inger

Søk i DiVA

Av forfatter/redaktør
Stavreus-Evers, AnneliKallak, Theodora KunovacSundström Poromaa, Inger
Av organisasjonen
I samme tidsskrift
Menopause: The Journal of the North American Menopause

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 666 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf